Next Generation Sequencing (NGS) Industry Outlook (2026-2036)

The growth of this market is mainly driven by rising cancer prevalence and the increasing application of NGS in cancer treatment and research, declining costs of genome sequencing, the surge in genome mapping programs, increasing pharmaceutical R&D expenditures, and improvements in regulatory and reimbursement scenarios for NGS-based diagnostic tests. In addition, the increasing application of NGS in personalized medicine, the rising adoption of bioinformatics and genomic data management solutions, and government initiatives supporting large-scale sequencing projects are expected to create growth opportunities for players operating in this market.

The global NGS Market is projected to reach USD 77,180.8 million by 2036, driven by clinical sequencing in oncology and reproductive health, national genome programs, falling sequencing costs, and the growth of outsourced sequencing and bioinformatics.

North America is expected to account for the largest market share of 43.9% in 2026, while Asia-Pacific is projected to register the fastest growth at a CAGR of 16.2% during the forecast period, and India is projected to register the highest CAGR of any country, at 18.3%.

By offering, the Commercial Sequencing/Outsourced Services segment is expected to account for the largest market share of 39.0% in 2026 and to register the highest CAGR of 14.8% during the forecast period.

By application, Research & Other Applications are expected to account for the larger share of 61.4% in 2026, whereas Clinical Applications are projected to register the higher CAGR of 14.7%, led by oncology at 15.6%.

Clinical and research demand have diverged: Illumina reported clinical sequencing consumables growing 20% excluding China, with more than 65% of sequencing consumables revenue now clinical, while research and applied consumables declined 12%.

High-throughput short-read platforms now deliver a human genome at approximately USD 200, MGI Tech states approximately USD 150 per genome on the DNBSEQ-T7, and Ultima Genomics announced a USD 100 genome for its UG100 platform.

Illumina led the instruments and consumables market with an assessed share of 42.4% in 2025, followed by Thermo Fisher Scientific at 23.2% and MGI Tech at 7.8%, while Eurofins Scientific led commercial sequencing services with 13.6%.

The NGS Market comprises the products and services used to determine the nucleotide sequence of DNA and RNA at scale: sample preparation kits, reagents and workstations; sequencing systems, consumables and services; data analysis software and informatics services; and commercial sequencing services provided on an outsourced basis. NGS is used in disease diagnostics, biomarker and drug discovery, precision medicine, reproductive health, infectious disease surveillance, and agriculture and animal research.

The economics of sequencing have changed fundamentally. High-throughput short-read platforms deliver a genome at approximately USD 200, and production whole genome sequencing at major sequencing centres is priced at USD 200 to USD 600 at 30x coverage. As a result, data analysis, comprising variant calling, annotation and interpretation, together with data storage, now costs more than the sequencing itself, which supports growth of the Data Analysis/Bioinformatics segment at a CAGR of 13.8%.

National population sequencing programs generate volume at a scale individual institutions do not reach. UK Biobank completed whole genome sequencing of 500,000 participants with more than GBP 200 million of investment, Genomics England has committed to sequencing 5 million genomes over five years and is sequencing over 100,000 newborns, and the National Project of Bio-Big Data of Korea targets whole genome sequencing for 550,000 individuals.

Clinical and research sequencing demand have followed different trajectories. Clinical sequencing, led by comprehensive genomic profiling, minimal residual disease testing, rare disease genomes and prenatal testing, continued to grow, while academic and government demand was constrained by a cut of nearly 40% to the National Institutes of Health budget for fiscal 2026. Thermo Fisher Scientific, QIAGEN, Agilent Technologies, Bio-Rad Laboratories and Tecan Group each reported constrained demand from academic and government customers.

On the supply side, competition is intensifying. Roche launched the AXELIOS 1 sequencing platform on June 29, 2026, reporting 2.3 terabases of concordant duplex bases per four-hour run, while Element Biosciences, Ultima Genomics, MGI Tech, PacBio and Oxford Nanopore Technologies compete on cost, read length and throughput.

Five factors are driving the growth of the NGS Market: rising cancer prevalence and the increasing application of NGS in cancer care, declining costs of genome sequencing, the surge in genome mapping programs, increasing pharmaceutical R&D expenditures, and improvements in regulatory and reimbursement scenarios. Together, these factors support growth of the NGS Market at a CAGR of 13.5% from 2026 to 2036.

The global cancer burden is rising steadily. According to the International Agency for Research on Cancer (IARC), there were an estimated 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, and 53.5 million people were alive within five years of a cancer diagnosis. IARC projects over 35 million new cancer cases in 2050, an increase of 77%, driven by population ageing and growth and by exposure to risk factors such as tobacco, alcohol, obesity and air pollution.

The most common cancers in 2022 were lung cancer (12.4% of all cancers), female breast cancer (11.6%), colorectal cancer (9.6%), prostate cancer (7.3%) and stomach cancer (4.9%). Lung cancer alone accounted for nearly 2.5 million new cases and 18.7% of cancer deaths. High Human Development Index countries are expected to see the largest absolute increase, with 4.8 million additional cases in 2050, while low and medium HDI countries face proportional increases of 142% and 99%.

NGS is used in cancer care to identify the genomic alterations driving tumor growth, select targeted therapies, detect resistance mutations and assess hereditary cancer risk. Each new patient for whom molecular characterization is clinically indicated adds sequencing volume, and comprehensive genomic profiling, liquid biopsy and minimal residual disease testing are increasingly repeated over the course of treatment. As a result, oncology is projected to register the highest CAGR among clinical applications, at 15.6% during 2026-2036.

The cost of sequencing a human genome has fallen substantially. High-throughput short-read platforms now deliver a genome at approximately USD 200, and production whole genome sequencing at major sequencing centres is priced at USD 200 to USD 600 at 30x coverage, while smaller cores and contract research organizations charge USD 600 to USD 1,500.

Competition among platforms continues to lower costs. The Illumina NovaSeq X Plus delivers a genome at approximately USD 200 with a capacity above 20,000 human genomes per year, the MGI Tech DNBSEQ-T7 is stated at approximately USD 150 per genome at less than half the instrument cost, and the DNBSEQ-T20x2 is stated at under USD 100 per genome at population scale. Ultima Genomics announced a USD 100 genome for its UG100 platform at AGBT 2024.

Lower cost per genome increases the number of samples that an institution can sequence within a fixed budget, which supports volume growth across research and clinical applications. However, downstream costs have not fallen at the same rate: data analysis, annotation, interpretation and storage now cost more than the sequencing itself. Thus, declining sequencing costs are driving market growth while shifting a larger share of spending toward the Data Analysis/Bioinformatics segment, which is projected to grow at a CAGR of 13.8%.

National population sequencing programs generate sequencing volume at a scale that individual institutions do not reach. UK Biobank completed whole genome sequencing of its 500,000 participants, requiring more than 350,000 hours of sequencing and over GBP 200 million of investment, funded by Wellcome, UKRI and four biopharmaceutical companies: Amgen, AstraZeneca, GSK and Johnson & Johnson. The earlier UK Biobank exome consortium sequenced 200,643 participants and found that approximately 2% carried a medically actionable genetic variant.

Other programs are scaling up. Genomics England sequenced 100,000 genomes from approximately 85,000 NHS patients and has committed to sequencing 5 million genomes over five years, its Newborn Genomes Programme is sequencing over 100,000 newborns, and Our Future Health aims to recruit up to 5 million adults. The National Project of Bio-Big Data of Korea targets whole genome sequencing for 550,000 individuals, including 60x sequencing of 41,000 cancer samples across 13 cancer types.

These programs consume instruments, consumables and library preparation reagents during sequencing and then generate sustained demand for data storage, analysis and interpretation, and several are extending into multiomics: All of Us released its first proteomics and transcriptomics data in June 2026. Because pharmaceutical companies fund population sequencing in exchange for data access, this demand is partly independent of public research budgets.

Pharmaceutical and biotechnology companies use NGS in target identification, mechanism studies, biomarker measurement, patient stratification for clinical trials and companion diagnostic development, which is why they are expected to account for the largest share of 43.1% of the NGS Market in 2026.

Sequencing has also become part of the evidence supporting drug approval. On April 12, 2024, the FDA Oncologic Drugs Advisory Committee voted 12 to 0 that data support the use of minimal residual disease as an intermediate endpoint for accelerated approval in multiple myeloma, based on meta-analyses of 42 clinical trials and 21,006 patients. On January 20, 2026, the FDA issued draft guidance defining the endpoint as minimal residual disease negativity assessed by flow cytometry-based or sequencing-based methods, which requires validated sequencing at defined timepoints in trials that use it.

Investment in sequencing-based diagnostics is also rising. Natera guided research and development spending of USD 800 million to USD 900 million for 2026, against USD 626 million in 2025, directed at clinical trials and early cancer detection. Thus, rising R&D spending and the acceptance of sequencing-derived endpoints are expanding demand from the industry.

Reimbursement determines whether a clinical sequencing test generates volume. In the U.S., National Coverage Determination 90.2 provides national Medicare coverage for NGS as a diagnostic test in cancer when performed in a CLIA-certified laboratory and ordered by a treating physician. Coverage for somatic testing, effective March 16, 2018, applies to patients with recurrent, metastatic, relapsed, refractory or stage III or IV cancer and requires an FDA-approved or cleared companion diagnostic, and coverage for germline cancer testing became effective on January 27, 2020.

Most other molecular tests reach coverage through the Molecular Diagnostic Services Program (MolDX), which requires a DEX Z-Code identifier and a technical assessment before payment, while Medicare Administrative Contractors may cover RNA sequencing and other NGS tests through Local Coverage Determinations. A test that achieves FDA approval as a companion diagnostic receives coverage automatically under the national determination, which makes companion diagnostic development the principal route to funded clinical volume.

As a result, reimbursement is converting clinical demand into paid testing, and the Hospitals & Diagnostic Laboratories segment is projected to register the highest CAGR among end users, at 14.4%.

The high costs of NGS systems, consumables and automation workstations, together with the availability of cheaper alternative technologies for targeted questions, restrain the growth of the NGS Market, particularly among lower-volume laboratories.

While the cost per genome has declined, the capital and operating costs of establishing sequencing capability remain substantial. High-throughput platforms carry instrument costs in the hundreds of thousands of dollars, and their flow cells and reagent cartridges are proprietary, so an institution that installs a system is committed to that manufacturer for the operating life of the instrument.

The Illumina NovaSeq X Plus carries an instrument cost more than twice that of the MGI Tech DNBSEQ-T7, and ultra-high-throughput platforms such as the DNBSEQ-T20x2 reach the lowest cost per genome only in specialized population genomics settings. Because a high-throughput instrument achieves its stated cost per genome only when operated at or near capacity, institutions with lower sequencing volumes face a materially higher effective cost per sample.

Thus, high system and consumable costs limit adoption among lower-volume institutions and shift their demand toward outsourced sequencing, which is one reason Commercial Sequencing/Outsourced Services are the largest and fastest-growing offering.

Library preparation involves many pipetting steps, and automating them requires a liquid handling workstation in addition to the sequencer, with the capital cost incurred before any sample is sequenced. Laboratories preparing a small number of libraries can work manually and cannot recover the cost of a workstation, while high-volume laboratories gain reproducibility and throughput that justify the investment. As a result, automation adoption remains concentrated in higher-volume institutions.

Several cheaper and established alternatives are used for molecular profiling, including microarrays, fluorescence in situ hybridization (FISH), PCR, array comparative genomic hybridization, pyrosequencing, multiplex ligation-dependent probe amplification (MLPA) and mass spectrometry. Sanger sequencing retains a defined position for single-gene work and clinical confirmation, producing high-accuracy reads of 800 to 1,000 base pairs.

Where the clinical question concerns a single known variant, a targeted method answers it at lower cost and with shorter turnaround than sequencing a panel or genome. Thus, alternative technologies continue to limit NGS adoption in narrowly defined testing applications.

Personalized medicine, bioinformatics and genomic data management, and government-funded sequencing programs are expected to create the largest growth opportunities for players operating in the NGS Market during the forecast period.

Precision medicine selects treatment based on the genetic makeup of a patient and of the disease, which reduces trial-and-error prescribing, avoids adverse drug reactions, improves adherence and allows failed drugs to be revived for genetically defined populations. NGS makes it possible to sequence multiple genes quickly and reliably from a single sample, and oncologists increasingly sequence biopsy samples to select drugs that target the alterations driving tumor growth.

Under National Coverage Determination 90.2, a test with FDA approval or clearance as a companion diagnostic receives national Medicare coverage automatically, linking precision medicine testing directly to funded clinical volume. Falling turnaround times, better bioinformatics and harmonized knowledge bases for interpreting results are further supporting adoption. As a result, Clinical Applications are projected to grow at a CAGR of 14.7%, compared with 12.7% for research and other applications.

A human genome sequenced at 30x coverage generates approximately 100 gigabytes of raw data in FASTQ format and approximately 80 gigabytes as aligned reads, so national programs sequencing hundreds of thousands of participants require dedicated storage and computing infrastructure. As sequencing costs fall, the share of total workflow spending on informatics rises correspondingly.

Machine learning is being applied to variant classification and risk modelling to improve the accuracy and clinical usefulness of results. Web and cloud-based software is projected to grow at a CAGR of 15.9%, compared with 10.6% for on-premise deployment, and data interpretation and reporting tools at 14.7%, making informatics one of the most attractive opportunities in the NGS market.

Government-funded sequencing programs operate across the major markets, including Genomics England, the Newborn Genomes Programme, Our Future Health, the National Project of Bio-Big Data of Korea, the All of Us Research Program, PRECISE in Singapore and Biobank Japan. These programs procure instruments, consumables, library preparation reagents and informatics capacity through single large procurement decisions rather than distributed institutional purchasing.

This concentrates a substantial share of sequencing demand in a limited number of large awards, which favors suppliers with high-throughput platforms, population-scale informatics and large service capacity. Thus, national programs are expected to create significant growth opportunities, particularly in Asia-Pacific, which is projected to grow at a CAGR of 16.2%.

Two challenges are expected to affect the NGS Market throughout the forecast period: the shortage of skilled professionals, especially for clinical interpretation, and the cost and complexity of storing, handling and protecting genomic data.

Operating a sequencing workflow requires personnel trained in library preparation, instrument operation, bioinformatics and clinical interpretation. The interpretive step is the most constrained, because classifying a variant as pathogenic, benign or of uncertain significance requires clinical genetics expertise that cannot be acquired quickly.

An institution can install additional sequencing capacity within months, while building interpretive capacity takes years, so the number of results it can report may be limited by staffing rather than by instrument throughput. Thus, the shortage of skilled professionals limits the conversion of installed capacity into reported results.

NGS data can be affected by alignment errors, sequencing errors and sample contamination, which can lead to false positives and false negatives with clinical consequences. Institutions must also decide how long to retain raw data, aligned reads and variant calls, each of which carries different storage costs and different potential for reanalysis as reference genomes and pipelines improve.

Genomic data identifies an individual and their relatives, and data protection frameworks in the major markets, such as the General Data Protection Regulation in Europe and the Health Insurance Portability and Accountability Act in the U.S., impose specific requirements on storage, processing and cross-border transfer. Thus, data governance remains a significant cost and a challenge for market stakeholders.

Six trends are reshaping the NGS Market: consolidation around multiomic portfolios, the divergence between clinical and research demand, the entry of new sequencing platforms, portable sequencing, automation of sample preparation, and the growth of single-cell and spatial sequencing.

Leading companies are using acquisitions and partnerships to extend beyond sequencing into adjacent technologies. Illumina completed the acquisition of SomaLogic in January 2026 for USD 350 million in cash plus up to USD 75 million in milestones, extending into proteomics; QIAGEN completed the acquisition of Parse Biosciences in December 2025, entering single-cell sequencing; and MGI Tech announced the acquisition of STOmics and CycloneSEQ in March 2026, adding spatial multiomics and nanopore sequencing.

Automation and AI partnerships are also growing: Tecan announced agentic AI developments for laboratory automation powered by NVIDIA in June 2026. Acquisitions and mergers accounted for 38.5% of the key growth strategies adopted by leading players between 2023 and 2026, showing that consolidation around multiomic portfolios is a defining trend.

Illumina reported that clinical sequencing consumables grew 20% excluding China for two consecutive quarters, with more than 65% of sequencing consumables revenue now derived from clinical applications, including comprehensive genomic profiling, rare disease whole genome sequencing and next-generation prenatal testing, while research and applied consumables declined 12%.

Other suppliers reported the same pattern. Thermo Fisher Scientific attributed flat analytical instruments revenue to muted academic and government demand in the U.S. and China, QIAGEN cited cautious U.S. life sciences demand, and Agilent Technologies reported academic and government revenue declines across all of its businesses in fiscal 2025. The U.S. government announced a cut of nearly 40% to the NIH budget for fiscal 2026, and NIH grant terminations disrupted at least 383 clinical trials covering more than 74,000 patients.

Asia-Pacific is an exception: Agilent Technologies recorded Asia-Pacific revenue up 14% in the quarter ended July 31, 2026, with strong growth in genomics. Thus, suppliers are reorienting toward clinical customers and Asia-Pacific markets.

Sequencing is no longer dominated by a single technology. Roche launched the AXELIOS 1 platform on June 29, 2026, built on sequencing-by-expansion chemistry, with company data showing 2.3 terabases of concordant duplex bases per four-hour run at Q38 accuracy or better and approximately 99% concordance with the leading technology across 118 tumor-normal pairs at 256 genomes per week. Roche assesses the NGS market at approximately USD 7.3 billion on a 2025 basis.

Element Biosciences and Ultima Genomics have entered with alternative chemistries designed to reduce cost barriers, and the Element AVITI competes in the mid-throughput segment with the MGI Tech DNBSEQ-G400 and Singular Genomics G4. Because Roche already has clinical diagnostics relationships across the major markets, its entry is expected to intensify competition for clinical sequencing customers.

Portable nanopore sequencers make sequencing possible outside large laboratories and can sequence an entire genome for less than USD 1,000. Nanopore reads extend to multi-megabase length, resolving structural variants, repetitive regions and complex genomic regions that short-read platforms characterize incompletely.

Oxford Nanopore Technologies reported revenue of approximately GBP 223.5 million in fiscal 2025 and GBP 116.7 million in the first half of 2026. Portable sequencing extends use to field pathogen surveillance and to laboratories that cannot accommodate high-throughput instruments.

As cost per genome has fallen and sample numbers have risen, manual library preparation has become the constraint on throughput in laboratories operating high-capacity sequencers. Tecan recorded full-year 2025 order entry of CHF 900.9 million, with first-half 2025 Life Sciences sales of CHF 185.7 million supported by clinical genomic testing, and launched the Veya multiomics liquid handling workstation in January 2025. The NGS Workstations segment is projected to grow at a CAGR of 12.8%.

Single-cell and spatial sequencing provide per-cell or anatomically resolved measurement and are now recognized as a distinct category of sequencing. QIAGEN acquired Parse Biosciences in December 2025, which was tracking ahead of a USD 40 million sales target for 2026, and MGI Tech announced the acquisition of STOmics in March 2026.

Single-cell library preparation consumes more reagents per sample than bulk sequencing, because each cell is processed separately, which increases consumable demand per experiment and supports growth in RNA library preparation, projected at a CAGR of 13.2%.

Based on offering, the global NGS Market is segmented into Sample Preparation, Sequencing, Data Analysis/Bioinformatics, and Commercial Sequencing/Outsourced Services. In 2026, the Commercial Sequencing/Outsourced Services segment is expected to account for the largest share of 39.0% of the market, and it is also projected to register the highest CAGR of 14.8% during the forecast period, because of the high cost of in-house sequencing capacity, national genome programs and the growth of clinical sequencing laboratories. Within services, Targeted Sequencing Services account for the largest share, while Methyl Sequencing Services grow fastest, at 15.6%.

The Sample Preparation segment, valued at USD 6,334.2 million in 2026, includes kits & reagents, which account for 86.5% of the segment, and NGS workstations. The Sequencing segment, valued at USD 4,608.3 million, includes consumables, NGS systems and services, with DNA nanoball sequencing projected to be the fastest-growing system technology, at 14.3%. The Data Analysis/Bioinformatics segment, valued at USD 2,338.6 million, includes software and NGS informatics services.

Based on application, the market is segmented into Research & Other Applications (Drug Discovery, Agriculture & Animal Research, and Other Applications) and Clinical Applications (Oncology, Reproductive Health, Infectious Diseases, and Other Clinical Applications). In 2026, the Research & Other Applications segment is expected to account for the larger share of 61.4% of the NGS market, led by drug discovery. However, the Clinical Applications segment is projected to register the higher CAGR of 14.7% during the forecast period, and within it, oncology is projected to grow at 15.6%.

Based on end user, the market is segmented into Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Laboratories, Academic Institutes & Research Centers, and Other End Users. In 2026, the Pharmaceutical & Biotechnology Companies segment is expected to account for the largest share of 43.1% of the NGS market, due to the heavy use of sequencing in drug discovery and clinical development. However, the Hospitals & Diagnostic Laboratories segment is projected to register the highest CAGR of 14.4% during the forecast period.

The global NGS Market combines sequencing platform suppliers, sample preparation and automation companies, bioinformatics providers and commercial sequencing service providers. Market participants compete on throughput and cost per genome, accuracy and read length, workflow integration, regulatory approvals, data analysis capability and global service reach.

Between 2023 and 2026, acquisitions and mergers accounted for 38.5% of the key growth strategies adopted by leading players, followed by product launches and enhancements at 29.2% and partnerships and agreements at 20.8%. In 2025, Illumina led the instruments and consumables market with an assessed share of 42.4%, followed by Thermo Fisher Scientific (23.2%) and MGI Tech (7.8%). Illumina also led data analysis/bioinformatics with 12.1%, Eurofins Scientific led commercial sequencing services with 13.6%, and Danaher led NGS workstations with 32.6%.

The report provides a comprehensive competitive assessment of the leading companies operating in the global NGS Market. The key players profiled in the report include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Eurofins Scientific SE (Luxembourg), BGI Genomics Co., Ltd. (China), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies plc (U.K.), Tecan Group Ltd. (Switzerland), Hamilton Company (U.S.), Hudson Robotics, Inc. (U.S.), LGC Limited (U.K.), Eppendorf SE (Germany), Novogene Co., Ltd. (China), GeneDx Holdings Corp. (U.S.), MGI Tech Co., Ltd. (China), and Quest Diagnostics Incorporated (U.S.).